Jijun Zheng

Jijun Zheng

Auto-generated profile, based on publicly available information

Jijun Zheng


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
JZJijun Zheng
Jijun Zheng
MZMaoyuan Zhao
Maoyuan Zhao
YZYuanhao Zhang
Yuanhao Zhang
JCJie Chen
Jie Chen
RLRuilin Li
Ruilin Li
JZJinhao Zeng
Jinhao Zeng
Chronic atrophic gastritis (CAG) is characterized by mucosal atrophy due to prolonged inflammation, leading to compromised mucosal barrier integrity and mitochondrial dysfunction. Artemisinin B (ATB), a derivative of artemisinin with potent anti-inflammatory properties, has shown therapeutic potential for CAG but is limited by poor oral bioavailability. To overcome this, an amino-functionalized BYON nanocarrier system (BYON-ATB) was developed, enhancing mucoadhesion through surface charge modification and enabling targeted drug release in the gastric environment. BYON-ATB significantly outperformed free ATB in reducing inflammation, oxidative stress, and barrier dysfunction, and importantly, promoted gastric atrophy regeneration in vivo. This regenerative effect was driven by the restoration of mitochondrial structure and function, including improved membrane potential, inhibited mPTP opening, and increased ATP production. Mechanistically, BYON-ATB upregulated the mitochondrial calcium uptake regulator MICU1, thereby restoring mitochondrial calcium homeostasis. This study highlights MICU1 as a promising therapeutic target in CAG and demonstrates that BYON-ATB facilitates gastric atrophy regeneration via inflammation, oxidative stress, and barrier disruption through MICU1-mediated mitochondrial calcium homeostasis.